EconPapers    
Economics at your fingertips  
 

Survival of pancreatic cancer cells lacking KRAS function

Mandar Deepak Muzumdar, Pan-Yu Chen, Kimberly Judith Dorans, Katherine Minjee Chung, Arjun Bhutkar, Erin Hong, Elisa M. Noll, Martin R. Sprick, Andreas Trumpp and Tyler Jacks ()
Additional contact information
Mandar Deepak Muzumdar: Massachusetts Institute of Technology
Pan-Yu Chen: Massachusetts Institute of Technology
Kimberly Judith Dorans: Massachusetts Institute of Technology
Katherine Minjee Chung: Massachusetts Institute of Technology
Arjun Bhutkar: Massachusetts Institute of Technology
Erin Hong: Massachusetts Institute of Technology
Elisa M. Noll: Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM)
Martin R. Sprick: Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM)
Andreas Trumpp: Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM)
Tyler Jacks: Massachusetts Institute of Technology

Nature Communications, 2017, vol. 8, issue 1, 1-19

Abstract: Abstract Activating mutations in the proto-oncogene KRAS are a hallmark of pancreatic ductal adenocarcinoma (PDAC), an aggressive malignancy with few effective therapeutic options. Despite efforts to develop KRAS-targeted drugs, the absolute dependence of PDAC cells on KRAS remains incompletely understood. Here we model complete KRAS inhibition using CRISPR/Cas-mediated genome editing and demonstrate that KRAS is dispensable in a subset of human and mouse PDAC cells. Remarkably, nearly all KRAS deficient cells exhibit phosphoinositide 3-kinase (PI3K)-dependent mitogen-activated protein kinase (MAPK) signaling and induced sensitivity to PI3K inhibitors. Furthermore, comparison of gene expression profiles of PDAC cells retaining or lacking KRAS reveal a role of KRAS in the suppression of metastasis-related genes. Collectively, these data underscore the potential for PDAC resistance to even the very best KRAS inhibitors and provide insights into mechanisms of response and resistance to KRAS inhibition.

Date: 2017
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-017-00942-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_s41467-017-00942-5

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-017-00942-5

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-19
Handle: RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_s41467-017-00942-5